ISAD’s September Digest highlights Beijing 2026, the role of pharmacists in atopic dermatitis care, and new research shaping …
Three-year ARCADIA data show sustained improvements with Nemluvio in skin lesions, itch, sleep and quality of life in …
Eczema advocates held 61 meetings with U.S. congressional offices, calling for better treatment access, insurance reform and continued …
Australia will add tacrolimus 0.1% ointment (Zematop) to the PBS, giving more than 143,000 people with moderate-to-severe atopic …
MEPs have for the first time acknowledged the disproportionate impact of skin diseases on women and girls, and …
EADV’s 2026 Congress spotlight highlights advances in atopic dermatitis, from early- and late-onset disease to childhood eczema and …
A data-driven study of 217 AmaXhosa children in South Africa used machine learning to uncover environmental, immune and …
EFA calls for the EU Biotech Act to prioritise affordable access, patient-centred research and prevention while supporting biotechnology …
The Journal of the European Academy of Dermatology and Venereology will end print publication and move fully online …
AbbVie completes its $10.9 billion acquisition of Apogee Therapeutics, adding zumilokibart and other promising immunology treatments to its …
Advances in atopic dermatitis treatment are transforming care, while research focuses on personalized therapies, real-world evidence and holistic …
New guidelines recommend further diagnostic testing when atopic dermatitis fails to respond to treatment, helping identify misdiagnosis or …
ISAD and ISPD marked World Atopic Eczema Day on September 14 by urging equitable, affordable access to the …
Phase 2b results show rezpegaldesleukin significantly improved eczema severity, itch and quality of life in adults with moderate-to-severe …